As the SARS-CoV-2 pandemic continues to rage world-wide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and reliability of commercially available high-throughput immunoassays. Our study demonstrates that, the administration of two doses of BNT162b2 vaccine elicited a robust SARS-CoV-2-specific immune response assessed up to three months after full vaccination in a cohort of 37 health care workers (HCWs). SARS-CoV-2 specific antibody response, evaluated by four commercially available chemiluminescence immunoassays (CLIA), was qualitatively consistent with the results provided by the gold-standard in vitro neutralization assay (NTA). However, we could not observe a correlation between the quantity of antibody detected by CLIA assays and their neutralizing activity tested by NTA. Almost all subjects developed a SARS-CoV-2 specific T cell response. Moreover, vaccinated HCWs developed a similarly protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion. These results underline the importance of a solid vaccine-elicited immune response and a robust antibody titer. We believe that these relevant results should be taken into consideration in the definition of future vaccinal strategies.

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response / D. Mileto, C. Fenizia, M. Cutrera, G. Gagliardi, A. Gigantiello, A. De Silvestri, A. Rizzo, A. Mancon, M. Bianchi, F. De Poli, M. Cuomo, I. Burgo, M. Longo, S. Rimoldi, C. Pagani, S. Grosso, V. Micheli, G. Rizzardini, M. Biasin, M. Gismondo, A. Lombardi. - In: EMERGING MICROBES & INFECTIONS. - ISSN 2222-1751. - (2021). [Epub ahead of print] [10.1080/22221751.2021.2004866]

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

D. Mileto
Primo
;
C. Fenizia
Secondo
;
G. Gagliardi;A. Gigantiello;A. De Silvestri;A. Mancon;I. Burgo;S. Rimoldi;V. Micheli;M. Biasin;M. Gismondo
Penultimo
;
2021

Abstract

As the SARS-CoV-2 pandemic continues to rage world-wide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and reliability of commercially available high-throughput immunoassays. Our study demonstrates that, the administration of two doses of BNT162b2 vaccine elicited a robust SARS-CoV-2-specific immune response assessed up to three months after full vaccination in a cohort of 37 health care workers (HCWs). SARS-CoV-2 specific antibody response, evaluated by four commercially available chemiluminescence immunoassays (CLIA), was qualitatively consistent with the results provided by the gold-standard in vitro neutralization assay (NTA). However, we could not observe a correlation between the quantity of antibody detected by CLIA assays and their neutralizing activity tested by NTA. Almost all subjects developed a SARS-CoV-2 specific T cell response. Moreover, vaccinated HCWs developed a similarly protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion. These results underline the importance of a solid vaccine-elicited immune response and a robust antibody titer. We believe that these relevant results should be taken into consideration in the definition of future vaccinal strategies.
Settore BIO/13 - Biologia Applicata
Settore MED/04 - Patologia Generale
Settore BIO/19 - Microbiologia Generale
9-nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
SARS CoV 2 mRNA vaccine BNT162b2 triggers a consistent cross variant humoral and cellular response.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.73 MB
Formato Adobe PDF
1.73 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/881765
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
social impact